Wednesday, February 10, 2010, 4:10pm SGT - The Singapore stock market closes in 50 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Immunogen Inc. (IMGN)

At 5:00AM SGT: 6.42 USD   0.00 (0.00%)  
 MORE ON IMGN 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 ImmunoGen, Inc. (NGM:IMGN) Delayed quote dataEdit
Last Trade:6.42 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:6.42
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:11.80
Day's Range:N/A - N/A
52wk Range:3.85 - 10.13
Volume:0
Avg Vol (3m):699,484
Market Cap:368.25M
P/E (ttm):N/A
EPS (ttm):-0.66
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add IMGN to Portfolio   Download Data

 HEADLINES 
•IMMUNOGEN INC Financials
EDGAR Online Financials (Thu, Feb 4)
•ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2010
Business Wire (Wed, Feb 3)
•ImmunoGen, Inc. Announces Webcast of Presentation at the 12th Annual BIO CEO & Investor Conference
Business Wire (Tue, Feb 2)
•Biotech Calendar: Key Dates for February
at TheStreet.com (Tue, Feb 2)
•New Star Analyst Rankings for ImmunoGen, Inc.
StarMine (Sat, Jan 30)
•Immunogen drops guidance after tough Q2
at bizjournals.com (Sat, Jan 30)
•IMMUNOGEN INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Jan 29)
•ImmunoGen, Inc. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript
at Seeking Alpha (Fri, Jan 29)
•IMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Jan 29)
•ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2010 Financial Results
Business Wire (Fri, Jan 29)
More Headlines for IMGN...
 ANALYST 
EPS Est (next year) (Jun-10) :-0.80
EPS Est (in 2 years) (Jun-11) :-0.47
Avg Rec (current)*:1.8
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses ...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices